Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | KDM2B | Q8NHM5 | 8/20 | 0.40 |
| ▸ | JAK3 | P52333 | 3/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25366282 | 1.00 | HRH3 (0.44) | HRH3HRH1KDM2BJAK3PTK2 | |
| SCHEMBL25364449 | 0.93 | JAK3 (0.43) | HRH3JAK3PTK2JAK2PTGS2 | |
| SCHEMBL30541584 | 0.91 | HRH3 (0.36) | HRH3HRH1JAK3PTK2JAK2 | |
| SCHEMBL25366890 | 0.91 | HRH3 (0.36) | HRH3HRH1JAK3PTK2JAK2 | |
| SCHEMBL30541663 | 0.89 | PTGS2 (0.38) | PTGS2GPR119 | |
| SCHEMBL30541593 | 0.89 | PTGS2 (0.36) | PTGS2GPR119 | |
| SCHEMBL25364439 | 0.89 | PTGS2 (0.36) | PTGS2GPR119 | |
| SCHEMBL25366145 | 0.89 | PTGS2 (0.38) | PTGS2GPR119 | |
| SCHEMBL24266306 | 0.87 | HRH3 (0.42) | HRH3HRH1KDM2BJAK3PTK2 | |
| SCHEMBL29399201 | 0.87 | HRH3 (0.42) | HRH3HRH1KDM2BJAK3PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4479407-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | Bristol-Myers Squibb Company (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2023159153-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-24 | — | — | WO | disclosed |